Challenges Seen With Novel Agents in Multiple Myeloma
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
Deepu Madduri, MD, assistant professor at Mount Sinai Hospital, discusses the biggest challenge oncologists currently face since the introduction of novel agents to the field of multiple myeloma.
At the start of her practice, lenalidomide (Revlimid) and bortezomib (Velcade) were the only 2 novel agents available for patients with myeloma. Now, there are monoclonal antibodies, checkpoint inhibitors, CAR T cells, and many more.
With so many novel and targeted agents appearing in the treatment landscape, it is hard to keep up with all of the latest data for these drugs. In most cases, there is still not enough information available on the overall survival or progression-free survival with these drugs, Madduri says.
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
